Induced Pluripotent Stem Cells Meet Genome Editing

Dirk Hockemeyer* and Rudolf Jaenisch

1Department of Molecular and Cell Biology, University of California, Berkeley, Berkeley, CA 94720, USA
2The Whitehead Institute for Biomedical Research and Department of Biology, MIT, Cambridge, MA 02142, USA

*Correspondence: hockemeyer@berkeley.edu
http://dx.doi.org/10.1016/j.stem.2016.04.013

It is extremely rare for a single experiment to be so impactful and timely that it shapes and forecasts the experiments of the next decade. Here, we review how two such experiments—the generation of human induced pluripotent stem cells (iPSCs) and the development of CRISPR/Cas9 technology—have fundamentally reshaped our approach to biomedical research, stem cell biology, and human genetics. We will also highlight the previous knowledge that iPSC and CRISPR/Cas9 technologies were built on as this groundwork demonstrated the need for solutions and the benefits that these technologies provided and set the stage for their success.

Reprogramming: “The Yamanaka Experiment”

Ten years ago Takahashi and Yamanaka reported on the “Induction of Pluripotent Stem Cells from Mouse Embryonic and Adult Fibroblast Cultures by Defined Factors” (Takahashi and Yamanaka, 2006). The hypothesis of this work was daring and stated that a small set of transcription factors, when ectopically expressed in a somatic cell, can reprogram it back into a pluripotent state. Retrospectively, the simplicity of the experiments that Yamanaka and colleagues used to test this hypothesis was beautiful: take a set of 24 candidate genes, selected mostly for their high and specific expression in pluripotent cells, and simultaneously express them in differentiated cells using integrating retroviruses. Identify cells that induced pluripotency via a selectable marker gene that is not expressed in somatic cells, but is preferentially activated in pluripotent cells. Next, narrow down the cocktail of genes to the minimal set of reprogramming factors (Klf4, Sox2, Oct4, and Myc, a.k.a. KSOM) by the process of elimination. Lastly, demonstrate that the resulting induced pluripotent cells have all the key features of their embryonic stem cell (ESC) counterparts, such as a stem cell-like expression profile, the ability to give rise to differentiated cells in teratoma formation assays, and their contribution to tissues in chimeric mice after blastocyst injections (Takahashi and Yamanaka, 2006).

These experiments had an immediate impact. They came at a time when the potential of pluripotent stem cells (PSCs) in research applications and regenerative medicine had widely been appreciated (Rideout et al., 2002) (Figure 1), but technical and ethical limitations presented a challenge that severely impeded major progress toward realizing their full potential. Decades before the study by Yamanaka, John Gurdon (Gurdon, 1962, 1963) had demonstrated that the epigenetic profile of a fully differentiated cell can be reprogrammed to a pluripotent state. From a set of key experiments Gurdon demonstrated that a nucleus taken from a differentiated frog cell and injected into an enucleated oocyte can give rise to a fully developed frog. This experiment illustrated that during differentiation no essential genetic material is lost and that the epigenetic changes that drive cellular differentiation can be reprogrammed to totipotency. Decades later, the cloning of the sheep “Dolly” also by somatic cell nuclear transfer (SCNT) demonstrated that Gurdon’s finding extended to mammals as well (Campbell et al., 1996).

SCNT and cell fusion experiments gave two additional insights that set the stage for the Yamanaka experiment. First, they demonstrated that the cytoplasm of an oocyte or an ESC contains diffusible transacting factors capable of reprogramming a somatic nucleus (reviewed in Ambrosi and Rasmussen, 2005). Second, successful derivation of mice by SCNT with nuclei of B cells as a donor, which had undergone VDJ-recombination, provided genetic evidence that terminally differentiated cells can be reprogrammed (Hochmedinger and Jaenisch, 2002). Though more challenging, SCNT was eventually successful in reprogramming human cells into human ESCs (hESCs) in 2014 (Yamada et al., 2014). While these experiments spoke for the possibility of cellular reprogramming, they also suggested highly sophisticated machinery and a complex biological process, making the success of the basic Yamanaka experimental approach even more astounding. Even today, the gradual pace of transcription-factor-mediated reprogramming remains one of the most fascinating facets of the Yamanaka experiment: epigenetic changes after fertilization as well as reprogramming by SCNT occur within a few hours, while reprogramming by the Yamanaka experiment requires significantly more time, generally several days and multiple cell divisions. Yet, both processes result in a functionally equivalent cellular pluripotent state in in vitro cultures that is capable of forming an entirely new organism.

Around the same time as the first mammalian SCNT efforts, James Thomson derived the first hESC lines (Thomson et al., 1998). He used a very similar strategy that had proven successful for Evans and Martin (Evans and Kaufman, 1981; Martin, 1981), culturing the inner cell mass outgrowth of explanted blastocystcs. However, it is interesting to note that human and mouse ESC (mESC) maintenance require distinct signaling networks and culture conditions. LIF/Stat3 is required for maintaining the undifferentiated state in mESCs and BMP4 can inhibit the MEK/ERK differentiation pathway resulting in mESC self-renewal. In contrast hESCs and hiPSCs do not require hLIF, and maintenance of pluripotency seems to rely mostly on FGF and MEK/ERK signaling, indicating species-specific requirements for culturing pluripotent cells. It seems likely that this difference can be attributed to a difference in the developmental stage.
that is captured in vitro from the outgrowth of the inner cell mass, where hPSCs cultured under standard conditions represent a later epiblast-like pluripotent stage (Brons et al., 2007; Tesar et al., 2007; Theunissen et al., 2014) (reviewed in Nichols and Smith, 2009).

Proof-of-concept experiments with cells differentiated from hESCs suggested that PSCs could be a source for cell replacement transplantation therapies and could provide a model system to understand early human development and cellular differentiation. However, ethical concerns, limited access to embryos, and the possibility of immune rejection were roadblocks that impeded the promise of hESCs.

In 2006 the “Yamanaka experiments” made the ethical debate about PSC research largely obsolete, as they established a robust method to derive human pluripotent cells without the use of human embryos. Furthermore, iPSC technology promised to solve complications that were anticipated from immune rejection of heterologous hESC-derived tissues, as it would allow the generation of patient-specific autologous pluripotent cells and derived tissue. The race to perform the key functional follow-up experiments began immediately. For the mouse system it was essential to establish that iPSCs could pass the most stringent test for pluripotency: germline transmission (Maherali et al., 2007; Okita et al., 2007; Wernig et al., 2007) and tetraploid complementation (Kang et al., 2008; Zhao et al., 2009).

For the human system the initial question was whether the same set of factors capable of reprogramming mouse cells would also work for human cells (Takahashi et al., 2007). Yamanaka and Takahashi quickly demonstrated that their factors also worked in human cells (Takahashi et al., 2007). However, additional experiments over that last 10 years in mouse and human cells also revealed that other sets of transcription factor combinations can be equally potent in reprogramming cells to a pluripotent state, providing valuable insights into the transcriptional pluripotency networks and how cells establish pluripotency (Buganim et al., 2012; Apostolou and Hochedlinger, 2013; Park et al., 2008; Takahashi and Yamanaka, 2015; Yu et al., 2007).

For the anticipated clinical application of iPSCs, it was important to demonstrate that reprogramming could be achieved without stably integrating the KSOM factors into the genome of the somatic cell. Such factor-free iPSCs were generated by independent methods such as the excision of reprogramming factors using the Cre/LoxP (Soldner et al., 2009) or the piggyBac system (Kaji et al., 2009; Woltjen et al., 2009) by avoiding integration of the reprogramming factors altogether using non-integrating viruses (Fusaki et al., 2009), episomal vectors (Yu et al., 2009), or direct transfection of the reprogramming factors as either mRNA (Warren et al., 2010) or protein (Kim et al., 2009). Initially, human cell reprogramming was quite inefficient compared to mouse cells, and thus several technical improvements were made to optimize hiPSC reprogramming protocols, culture conditions, and iPSC characterization procedures to test for the pluripotency of newly isolated iPSCs. Eventually, these optimizations made iPSC technology increasingly more accessible to laboratories without previous stem cell experience and are now so streamlined that iPSC derivation, maintenance, and differentiation are widely used research tools in all aspects of biomedical research. In addition, efficient and robust reprogramming techniques provided insight into the mechanistic steps of reprogramming and the order of events involved in reverting the epigenome from a differentiated to a pluripotent state. A detailed understanding of the forces at work is necessary to answer the key questions of whether the reprogramming of human cells results in a cell state that is equivalent to hESCs or whether iPSCs retain to some extent an epigenetic memory (Maherali et al., 2007; Okita et al., 2007; Wernig et al., 2007) and tetraploid complementation (Kang et al., 2009; Zhao et al., 2009). For example, do iPSCs derived from liver cells retain some characteristics of liver cells and do they preferentially differentiate into liver tissue relative to other cell types? Tetraploid complementation and germline transmission experiments gave the clear answers that mouse iPSCs were fully reprogrammed to pluripotency. However, these tests are not available for hiPSCs. Moreover, it is not clear to what extent the mouse iPSC’s epigenome is reset during the reprogramming process and how much of the resetting occurs in vivo or when the cells pass through the germline. It is not surprising that early cellular stages of the reprogramming process will show epigenetic differences, yet all these differences eventually will converge on the same pluripotent cell state as ESCs. Thus, it is interesting to further examine the level and functional relevance of epigenetic memory; yet it seems that such
epigenetic differences in cellular state are at best small and over-shadowed by differences caused by the reprogramming method of choice, cell selection during propagation, culture conditions, and more importantly genetic background of the parental somatic cell (Guenthner et al., 2010; Kytta et al., 2016; Rouhani et al., 2014). For example, it has been demonstrated that the epigenetic memory, i.e. epigenetic characteristics reflecting the state of the donor cells seen initially in the iPSCs, is lost upon prolonged cell passages, suggesting that this donor-cell-specific memory may be of little functional relevance (Polo et al., 2010).

The most attractive application of the iPSC technology is that it allows the isolation of patient-derived cells that carry all genetic alterations that cause the particular disease. Thus, these cells provide an experimental system to study pathogenesis of the disease in an in vitro system and to possibly devise therapeutic strategies (Robinton and Daley, 2012). Importantly, the iPSC technology allows comparison of the neuroanatomical features and physiology of the iPSCs to the clinical features of the donor patient.

The Power and Limitations of iPSCs
In addition to the prospect of future iPSC-based cell replacement therapies, the ability to derive iPSCs from patients’ cells had a striking effect on human disease modeling. Some of the most remarkable advances were made in diseases such as neurodegenerative diseases that are only partially recapitulated in animal models. Here, iPSC technology was particularly transformative, as it made it possible to study the effects of familial monogenic diseases as well as complex idiopathic diseases in the context of patient-derived neurons and tissue, systems that were previously not readily available for experimental investigation. For example, studying dopaminergic neurons differentiated from Parkinson patient-derived iPSCs yielded insights into the molecular causes of the disease and the identification of cellular stressors that might exacerbate the phenotype (Soldner et al., 2011; Soldner and Jaenisch, 2012). As a result of such advances, iPSC-based and primary tissue culture systems have largely replaced previous experimental systems that studied human genetic diseases using overexpression studies in cancer cell lines. Indeed, the number of human diseases modeled in culture using patient-derived iPSCs (“disease in the dish”) is growing rapidly (summarized in Aivor et al., 2016; Sterneckert et al., 2014).

While the approach of studying human disease in the disease-relevant cell type resulted in many success stories and insights, several challenges of iPSC disease modeling quickly became apparent. For one, it became evident that many protocols that were developed for the differentiation of hPSCs into functional tissue resulted in embryonic rather than adult human cell types (Bedada et al., 2015; Forster et al., 2014; Hrvatin et al., 2014; Spence et al., 2011; Takebe et al., 2013). This observation might not pose a problem for studies that aim to recapitulate cell-autonomous defects of developmental diseases that likely will become apparent after a few weeks of in vitro differentiation. However, iPSC differentiation experiments that aim to understand human disease and pathologies within the context of the adult or as a function of human aging suffer from a lack of cellular maturity as well as a relatively short time span limited by culture conditions. One approach to increase the maturity of in vitro cell systems and to mimic cellular aging is to expose these cells to stressors that are associated with aging (Miller et al., 2013; Studer et al., 2015). Significant progress has also been made to current strategies of investigating cell non-autonomous biological problems, including the development of co-culture experiments and protocols to differentiate hPSCs into tissue stem cells and organoid cultures. Organoid cultures are small functional tissue units composed of several distinct cell types that can be maintained and used to recapitulate features of tissues rather than that of individual cell types in vitro (Lancaster et al., 2013; Sato et al., 2011; Sato et al., 2009) (reviewed in Lancaster and Knoblich, 2014; Sato and Clevers, 2013).

An important and often ignored challenge of iPSC technology is the variability between individual iPSC lines in their potential to differentiate into functional cells of a given lineage. This variation between cell lines is unpredictable and mostly caused by genetic background differences as well as the reprogramming history of a given cell line. Thus, in efforts to model a disease, detection of small phenotypic differences between cells differentiated from a patient or control iPSCs may not reveal a disease-relevant phenotypic difference but rather reflect the system’s immanent variation between individual iPSC lines (Soldner and Jaenisch, 2012). The generation of isogenic pairs of disease-specific and control iPSCs that differ exclusively at the disease-causing mutation has been used to control for the variation and has led to defining subtle disease-relevant differences in monogenic diseases (Soldner et al., 2011). The problem is, however, exacerbated when studying more clinically important sporadic or polygenic diseases where low-effect-size, disease-causing loci are defined by genome-wide association studies (GWASs). Since phenotypic differences would be expected to be small, the use of isogenic pairs of disease-specific and control cells would be even more important. Finally, ongoing efforts to learn about human genetic variation by studying dozens or even hundreds of iPSC lines derived from healthy donors may give little interpretable information because of the unpredictable system-inherent phenotypic variability between individual iPSC lines (differing in millions of SNPs within each genome) and experimental variations in their differentiation. Making isogenic iPSC controls by genome editing that differ only in a single or a few SNPs could reduce variations due to genomic variability.

The challenge associated with the genetic variability of hPSCs is compounded by another remarkable difference between mouse and human PSCs: the striking resilience of hPSCs to conventional gene targeting approaches. This dearth of genetic control in hPSCs prevented genetic experiments that were considered standard in mESCs. Nevertheless conventional gene targeting has been accomplished in hPSCs (Zwaka and Thomson, 2003). Protocols for conventional gene targeting have been optimized to modify hPSCs (Costa et al., 2007; Davis et al., 2008a; Irion et al., 2007; Ruby and Zheng, 2009) and have been successfully used to establish hPSC models for human disease such as Lesch-Nyhan syndrome (Urbach et al., 2004). Moreover, this approach has been used to correct the disease-causing mutation with ornithine-d-aminotransferase that is mutated in patients with gyrate atrophy (Howden et al., 2011) or to alter the amount of disease-causing CAG repeat expansions in the huntingtin gene of patient-specific iPSCs (An et al., 2012). Furthermore, these protocols have been used to generate lineage reporters for genes such as MIXL and Olig2 to study cell
fate decision of differentiating human stem cells (Davis et al., 2008b; Xue et al., 2009). Overall, however, these approaches are very time consuming, as they generally require the generation of large targeting constructs and even then are very inefficient and in many cases not successful. It appears that cell-intrinsic features such as low homologous recombination and single-cell survival rates make conventional genome modification as described by Capecchi and Smithies for mESCs (Doetschman et al., 1987; Thomas and Capecchi, 1987) very inefficient in hPSCs.

Both of these challenges have been overcome: the development of the Rho-kinase inhibitor Y-27632 to suppress anoikis during the disaggregation of hPSC colonies dramatically increased single-cell survival of hPSCs (Watanabe et al., 2007), and the low frequency of spontaneous homology-mediated gene targeting in hPSCs was dramatically increased through the development of site-specific nucleases (SSNs) as a tool for their genetic engineering (reviewed in Carroll, 2014; Hsu et al., 2014; Urnov et al., 2010).

**Genome Editing BC (Before CRISPR/Cas9)**

The development of SSNs as research tools parallels the development of iPSCs: key experiments uncovered the biological principles and highlight how a generalized platform for genome editing would advance basic and biomedical research. Repurposing of the CRISPR/Cas9 system as an engineered SSN removed the impediments that limited the full potential of genome editing by providing this general platform.

Key experiments more than 15 years ago in mammalian cells demonstrated that a double-strand break (DSB) generated by an SSN at a defined genomic site can be repaired either by the endogenous homology-mediated repair machinery using an exogenous provided repair template or by the error-prone non-homologous end joining (NHEJ)-DNA repair pathway (Rouet et al., 1994a, 1994b). The crucial observation made during these experiments was that a DSB increased the rate of homology-mediated genomic changes at the break site by several orders of magnitude compared to conditions in which only an exogenous repair template was provided without the induction of a DSB. Importantly, this principle of employing a DSB to facilitate DNA-repair mediated editing of genomes proved to be almost universal and applies to hPSCs as well as other systems such as Caenorhabditis elegans (Morton et al., 2006; Wood et al., 2011) and Drosophila melanogaster (Beumer et al., 2008; Bibikova et al., 2002, 2003), which are similarly resilient to conventional gene-targeting strategies as hPSCs are.

Already in 2005, Urnov et al. demonstrated that engineered zinc finger nucleases (ZFNs) can serve as a designer SSN to correct X-linked SCID disease-relevant mutations in patient-specific cells (Urnov et al., 2005). It was this study that coined the term “genome editing.” Ten years later the first clinical trials based on this ZFN technological platform are underway to disrupt CCR5 in T cells to treat HIV patients (Tebas et al., 2014).

Based on these pioneering experiments, we and others implemented the use of SSNs such as ZFNs and transcription activator-like effector nucleases (TALENs) to engineer hPSCs (DeKelver et al., 2010; Hockemeyer and Jaenisch, 2010; Hockemeyer et al., 2009, 2011; Lombardo et al., 2007; Sexton et al., 2014; Soldner et al., 2011; Zou et al., 2009). These experiments provided proof of principle for SSN-mediated gene knockouts, for the insertion of transgenes into expressed and non-expressed genes to generate cell-type-specific lineage reporters, for the overexpression of transgenes from genetically defined loci, and for the insertion or repair of disease-relevant point mutations in hPSCs (Figure 2).

The technical advances that established genetic control in hPSCs proved to be highly synergistic with the development of iPSC technology. Genome editing in hPSCs overcame the issue of enormous genetic background variability inherent in iPSC-based disease models. Independent proof-of-concept studies demonstrated that SSNs can be used to repair or introduce disease-relevant mutations in hPSCs (Soldner et al., 2011; Yusa et al., 2011). The resulting pairs of PSC lines are isogenic, except for the disease-relevant mutation. Parallel differentiation of such isogenic sets of cells into disease-relevant cells and tissues can be used to directly assess the contribution of a mutation to cellular pathology (Chung et al., 2013; Ryan et al., 2013; Wang et al., 2014b; Yusa et al., 2011).

The initial ZFN and TALEN platforms to generate SSNs for genome editing in stem cells were costly and labor intensive and their implementation as research tools therefore developed comparatively slowly. However, extensive work with ZFNs and TALENs has demonstrated the power of genome editing and highlighted the impact that a universal, cheaper, and simpler platform to make SSNs would have.

**CRISPR/Cas9: Everyone Can Edit Anything**

The need for a simple and unified platform to generate SSNs was met and resolved, similarly to the need for an easy way to make iPSCs, through a single experiment: by repurposing the bacterial Clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated (Cas) adaptive immune systems (reviewed in Marraffini, 2015) as an SSN. In 2012 the collaborative work of the Jennifer Doudna and Emmanuelle Charpentier laboratories demonstrated that in CRISPR type-2 systems a single protein, Cas9, can function as a designer SSN by associating with an engineered single guide RNA (sgRNA) that bears homology to a genetic locus of interest (Jinek et al., 2012). In this process, the sgRNA substitutes the natural Cas9-associated bacterial RNAs that normally confer target specificity for the bacterial pathogen DNA and instead directs Cas9 to introduce a blunt DSB in any target DNA with complementarity to a 20-nucleotide (nt)-long sequence in the sgRNA. Doudna and colleagues predicted that this simple way of engineering SSNs could be exploited to streamline genome editing (Jinek et al., 2012). In less than 4 years this prediction became reality and Cas9-mediated genome engineering was developed into the platform of choice to generate SSNs and to genetically modify hPSCs (Chen et al., 2015; Cong et al., 2013; Fu et al., 2014; González et al., 2014; Kleinistiver et al., 2015; Hou et al., 2013; Hsu et al., 2014; Kleinistiver et al., 2016; Liao and Karnik, 2015; Lin et al., 2014; Mali et al., 2013; Ran et al., 2015; Slaymaker et al., 2016; Tsai et al., 2014; Wu et al., 2014b). Some important adaptations and improvements to increase the ease and scope of Cas9-mediated genome engineering in hPSCs were the establishment of CRISPR/CAS-systems from different organisms (Hou et al., 2013; Zetsche et al., 2015) that respond to different PAM sequences and the engineering of spCas9 to associate with
alternative PAMs by structure-based engineering of Cas9, thereby extending genomic target range and specificity of spCas9 (Kleinstiver et al., 2015a; Kleinstiver et al., 2015b). Furthermore, several detailed protocols that describe the implementation of genome editing techniques in PSC systems have been optimized and published (Blair et al., 2016; Byrne and Church, 2015; Chiba and Hockemeyer, 2015; Yusa, 2013).

The key advantage of the CRISPR/Cas9 system over previous systems lies in the fact that DNA-binding specificity is encoded solely by the sgRNA and so unlike previous platforms does not require laborious engineering of DNA binding proteins. Thus CRISPR/Cas9-based editing has largely replaced previous SSN technologies. Combining the cellular versatility of iPSC differentiation with the ease of CRISPR/Cas9-mediated genome editing proved to be a very powerful experimental approach, and by now genome editing in hPSCs has become a standard tool in stem cell research and human disease modeling (Johnson and Hockemeyer, 2015; Matano et al., 2015; Schwank et al., 2013).

One of the most exciting experiments that became possible since the development of robust and highly efficient editing technologies in hPSCs is the genetic and functional testing of the onslaught of empirical data generated by GWASs. Similar to the disease-modeling approach, genome editing allows us to engineer variant alleles observed in these studies found to be associated with a specific disease in an otherwise isogenic cellular setting. Phenotypic comparison of such cells can reveal how non-coding mutations, enhancer polymorphisms, and balancer...
mutations can impact tissue-type-specific cellular behaviors that are relevant to the particular condition. For example, this approach has been used successfully to identify the molecular principles underlying the most frequent non-coding mutations associated with human cancer (Bojesen et al., 2013; Fredriksson et al., 2014; Horn et al., 2013; Huang et al., 2013; Killela et al., 2013). Genetic engineering of these mutations, which occur in the promoter of the catalytic subunit of human telomerase or TERT, revealed that the mutations result in the failure of cells to silence TERT transcription upon cellular differentiation and explains how these mutations function in tumorigenesis (Chiba et al., 2015).

Gene-correction frequencies in hPSCs are generally much lower than in tumor cell lines such as K578 or HCT116 cells that are commonly used for gene editing in cancer cells. A very elegant approach to overcome this challenge and to increase the efficiency of homology-mediated events in iPSCs was used in experiments that employed zinc finger nucleases to correct mutations in iPSCs derived from patients with alpha trypsin deficiency. In these experiments gene targeting efficiencies were increased by the use of a positive selection marker that allowed the efficient isolation of the edited clones and that could subsequently be removed without leaving residual genetic material using piggyBac transposition. This editing strategy allowed the generation of bi-allelic editing events in patient-derived iPSCs to restore alpha trypsin enzymatic function in disease-relevant iPSC-derived hepatocytes in vitro and after xenotransplantation (Yusa et al., 2011).

A similar approach to overcome the challenges associated with the low frequency of gene-correction events in hPSCs was used to correct point mutations in the beta-globin gene of iPSCs derived from patients with sickle cell disease (Zou et al., 2011). In this case a LoxP-site flanked selection cassette was used to increase the genome editing efficiency initially, but was then subsequently removed using Cre-recombinase. This approach results in a single residual LoxP site in an intron of the beta-globin gene. Similarly, two independent studies demonstrated that the SSN can be used to directly correct beta-thalassemia mutations in patient-derived iPSCs and restore hematopoietic differentiation (Ma et al., 2013; Xie et al., 2014).

Alternative strategies for increasing editing efficiencies include methods to more efficiently detect and subclone cells that have undergone rare editing events (Miyaoaka et al., 2014) as well as to enhance delivery methods for the nuclease and donor template (Lin et al., 2014). An orthogonal approach to simplify the generation of isogenic hPSC lines was the derivation of an inducible Cas9-expressing cell line by editing a Cas9 expression cassette into the AAVS1 locus. In this system Cas9 expression can be induced by doxycycline so that efficient editing afterward only requires the expression or delivery of the sgRNA (González et al., 2014). This system has been used to generate loss-of-function alleles in EZH2 and to demonstrate the effects of haploinsufficiency for EZH2 in hematopoietic differentiation (Kotini et al., 2015).

Further developments that facilitate the derivation of genome-engineered iPSC cell lines are protocols that directly combine genome editing with reprogramming. Howden et al. demonstrated that human fibroblasts could be simultaneously reprogrammed and edited, resulting in edited iPSCs going through only one single-cell cloning event without the need for drug selection (Howden et al., 2015).

Further implementation of gene-editing in patient-specific iPSCs will have a substantial impact on current disease modeling approaches. An example of the far-reaching effects is illustrated by editing experiments that inserted an inducible Xist IncRNA into chromosome 21 of Down syndrome patient-derived iPSCs. Using this approach Jiang et al. showed that ectopic expression of Xist was sufficient to transcriptionally suppress the targeted third copy of chromosome 21 and to reverse the cellular disease phenotypes in in vitro differentiated cells (Jiang et al., 2013).

Since the implementation of genome editing in hPSCs, several diseases have been modeled using isogenic cell lines that have either corrected a disease-relevant mutation in iPSCs or introduced a disease-relevant allele in wild-type hPSCs. For example, the genetic correction of mutations in Niemann-Pick type C patient-specific iPSCs to rescue metabolic defects in cholesterol metabolism and autophagy, which are responsible for the pathology, represents just one demonstration of how this approach has been successfully implemented (Maetzel et al., 2014). Furthermore, genome editing in hPSCs has been used to establish models for Rett syndrome disrupting MECP2 function in hPSCs (Li et al., 2013), to generate HIV-resistant variants alleles of the CCR5 gene into iPSCs (Ye et al., 2014), to repair MYO15A in iPSCs derived from patients affected by deafness (Chen et al., 2016), and to derive isogenic cell pairs of COL7A1-corrected iPSCs derived from patients with dystrophic epidermolysis bullosa (Sebastiano et al., 2014).

In a growing number of cases, such approaches have also been used to provide new insight into disease pathology. For example, SSN-mediated correction of disease-causing mutations in LRKK2 that are associated with Parkinson disease (PD) revealed the transcriptional changes caused by disease-associated alleles in patient cells (Reinhardt et al., 2013). Likewise, genome editing of patient-specific iPSCs followed by in vitro differentiation was also used to generate an isogenic disease model for cystic fibrosis by correcting disease-relevant mutations in CFTR followed by differentiation into airway epithelium (Crane et al., 2015; Firth et al., 2015; Suzuki et al., 2016).

**The Challenge of Studying Sporadic (Polygenic) Diseases**

The application of iPSC technology for the study of sporadic diseases poses particular challenges because disease-specific phenotypic changes are expected to be subtle. The genetic basis of sporadic or idiopathic diseases is thought to be a combination of multiple low-effect-size risk alleles, mostly in regulatory regions such as enhancers, which are identified by GWASs (Gibson, 2011; Merkle and Eggan, 2013). The “common disease-common variant hypothesis” proposes that multiple risk variants with small effect size in combination with additional environmental factors are the drivers of sporadic diseases. Thus, a major challenge of using human-derived cells is that risk variants are not only present in patients but also in unaffected individuals, albeit with lower frequency. Thus, individual risk variants are not sufficient to cause disease-associated phenotypes in carrier individuals or in hiPSCs derived from carriers or patients. While an iPSC isolated from a patient would harbor all risk variants that contribute to the disease, any in vitro study to gain mechanistic insights is complicated by the high system-immanent variability in differentiation into the disease-relevant cells (Soldner and Jaenisch, 2012). Another complicating factor is that the likely effect of
a GWAS-identified risk regulatory allele on the target gene (or genes) would be predicted to be subtler than would be expected for monogenic diseases as discussed above. Thus, it would be impossible to compare the disease-specific cells to a suitable control cell line because any control cells would have a different genetic background, which will affect the differentiation potential of the cells and thus would prevent a meaningful comparison.

Thus, a major challenge for using iPSCs for the study of sporadic diseases is how to generate pairs of isogenic cells that differ at one or multiple risk alleles. Figure 3 outlines a possible strategy of how the CRISPR/Cas9 gene editing approach could be used to generate isogenic cells that differ at multiple risk loci and thus would enable the mechanistic study of polygenic diseases. This approach was recently used to decipher the impact of PD-associated risk variants. Genetic engineering of a common PD-associated risk variant in a non-coding distal enhancer resulted in deregulation of SNCA expression, a key gene implicated in the pathogenesis of PD, by as little as 10% (Soldner et al., 2016). In order to detect such subtle gene expression differences, an allele-specific assay was developed that allowed the analysis of cis-acting effects of candidate variants on allele-specific gene expression as a consequence of deletion or exchange of disease-associated regulatory elements. Detailed analysis of isogenic cells with and without the risk allele further demonstrated that a single base pair change causes loss of transcription factor-binding sites for the transcription factors that otherwise function as a suppressor of SNCA transcription on a non-risk-associated allele.

Epidemiology and population genetics suggest that Sporadic Alzheimer Disease (SAD) results from complex interactions between genetic risk variants and environmental factors. In another approach to study risk alleles, patient-derived hiPSCs were used to dissect the effect of common SAD-associated non-coding genetic variants in the 5’ region of the SORL1 (sortilin-related receptor, L(DLR class) A repeats containing) gene involved in intracellular vesicular trafficking (Young et al., 2015). While initial experiments did not identify a consistent correlation between SORL1 expression and either disease status or risk haplotype, a small but significant correlation between the SAD-associated SORL1 haplotype and the BDNF-dependent response of SORL1 expression was found.

**Nuclease Specificity and Off-Target Considerations**

SSNs are enzymes that are targeted to specific sites in the genome, but their specificity can vary and promiscuous binding to so-called off-target sites can lead to unwanted cutting and modifications. Strategies to predict, identify, and reduce these off-target events are largely dependent on the SSN design, organism, and cell type and have already been to some extent implemented in hPSCs. Understanding the frequency and impact of off-targets is highly relevant to the development of SSNs for clinical applications and their reliable use in basic research (Gabriel et al., 2011).

Several studies recently addressed the specificity of Cas9 and its off-target action (reviewed in Wu et al., 2014a). Genome-wide binding studies of dCas9 expressed in mESCs demonstrated that Cas9 can associate with a large number of genomic sites, but off-target cutting of the catalytically active Cas9 at a subset of these sites was infrequent (Wu et al., 2014b). Similarly, single-molecule imaging of Cas9 in living cells has demonstrated that Cas9 searches for target sites by 3D diffusion and that, in contrast to on-target events, off-target binding events are, on average, short-lived (<1 s) (Knight et al., 2015).

While these data argue for the high specificity of Cas9, data in cancer cells suggest that off-targets can be frequently detected (Frock et al., 2015; Fu et al., 2014; Tsai et al., 2015; Wang et al., 2015b). For example, when using GUIDE-seq (Tsai et al., 2015), a protocol optimized in U2OS and HEK293 to detect off-targets more reliably than other methods such as ChIP-seq, Tsai et al. found many off-targets that computational algorithms had failed to predict. Based on these datasets Tsai et al. proposed that shorter guide sequences that only have about 17-nt homology to the target sequence would improve specificity (Fu et al., 2014). Moreover, the GUIDE-seq protocol was also used to engineer CRISPR-Cas9 nucleases with altered PAM specificities (Kleinsteiver et al., 2015a, 2015b) and reduced off-targets (Kleinsteiver et al., 2016).

An alternative protocol called BLES-seq, based on directly labeling the DSBs generated by the nuclease in situ followed by enrichment through streptavidin affinity purification and next-generation sequencing (Crosseto et al., 2013), was originally developed to detect DSBs caused by replicative stress by stalled replication in HeLa cells and mouse B lymphocytes. This protocol was further developed to assess Cas9 off-target frequencies of Cas9 and to rationally engineer Cas9 nucleases with improved specificity (Ran et al., 2015; Slaymaker et al., 2016).
Most experiments that have detected significant off-targets have been performed in cancer cells, which may have altered repair pathways that could affect recombination (Fu et al., 2013; Hsu et al., 2013). In contrast, experiments in whole organisms such as mice (Wang et al., 2013), primates (Niu et al., 2014), Zebrafish (Auer et al., 2014), or C. elegans (Dickinson et al., 2013) reported off-target frequencies that were low or not detectable, consistent with high specificity of the CRISPR/Cas9-mediated gene targeting. It is also possible that in non-transformed cells off-target cleavages are efficiently counter-selected by the endogenous DNA-damage response. As hPSCs are primary cells with genetically intact check-points it seems possible that off-targets will accumulate less frequently in hPSCs than has been observed in cancer cells. To address this it will be important to determine to what extent off-targets are the result of impaired checkpoint control of cancer cells and whether there are specific cell types and conditions that are predisposed for the accumulation of off-targets. Data from conventional whole-genome sequencing of hPSCs exposed to Cas9 have so far been limited and do not yet fully address the issues due to small sample sizes (Park et al., 2015; Smith et al., 2014).

Understanding how to avoid off-target SSN modification is of particular concern for the eventual clinical application of edited cells. For basic research, however, it seems that the necessary experiments are readily available to control for the effects of eventual off-target action of SSNs. Experiments to adequately address off-target concerns include: (1) the use of several independent guide RNAs to generate a mutant cell line, (2) complementation of loss-of-function phenotypes, and (3) secondary editing of the mutant cell line to revert the mutation to a WT allele followed by confirmation of phenotypic rescue.

**Large-Scale Screens, Epigenetic Editing, and Other Applications for Cas9 in iPSCs**

In addition to allowing the easy, fast, and inexpensive editing of hPSCs, the advent of Cas9 as a programmable DNA-binding protein allowed the development of forward genetics methodologies that were previously not readily available in hESCs. It is trivial to multiplex guide RNA synthesis, which allows the generation of large barcoded libraries of sgRNAs with several-fold coverage of every gene in the human genome. These libraries can be employed in loss-of-function screens, for example, to identify gene products that are required for drug resistance or the mediation of viral cell death (Gilbert et al., 2014; Hart et al., 2015; Parnas et al., 2015; Shalem et al., 2014; Shi et al., 2015; Wang et al., 2015a; Wang et al., 2014a; Zhou et al., 2014) (Figure 2). Most of the experiments that employ genome-wide screens have been done in cancer cells that can be expanded to accommodate the large numbers of cells that are required to perform these types of genome-wide screens. For the general implementation of these screening approaches in hPSCs or cells differentiated from hPSCs, it will be important to develop protocols that allow the expansion of these cells into large homogenous populations that in turn allow robust selection or enrichment for cellular phenotypes.

It is worth mentioning that the combination of iPSCs and genome editing has not only become a game changer for our approaches to human disease modeling, but it also provides an unprecedented opportunity to study the fundamental principles of cell biology. Previously, cell biologists mostly used aberrant cancer cell lines with often unstable and poorly defined genomes to describe human cellular behavior. This is mainly because human cancer cells presented the only reliable source of human immortal cells that could be expanded sufficiently to facilitate biochemical and genetic experimentation and could be indefinitely propagated, frozen, shipped, and shared between labs. This monopoly of cancer cells as a model system was broken with the advent of hiPSCs and the general availability of hPSCs. Like cancer cells, hPSCs are immortal, but they do not suffer from the disadvantages of the pathologically altered genomes of cancer cells and yet they still retain the capacity to differentiate into any cell type of interest. The combination of hPSCs with the power of genome editing can now be used to study specific aspects of human cell biology. Exploiting this potential will be particularly important in areas of research where fundamental biological processes, such as tumor suppression, cellular immortality, or neuronal biology, diverge between human and other species. Efforts, such as the one launched by the Allen Institute for Cell Science to generate an industrial-scale library of characterized iPSCs that will be used to create a visual, animated model of the cell, suggest that iPSCs will soon replace cancer cells as a model system for basic cell biology (Callaway, 2014).

In the same way that iPSC technology had broad impacts far beyond regenerative medicine and disease modeling, the impact of the discovery of CRISPR/Cas9 on hPSCs is not only its ability to act as an SSN. Catalytically inactive forms of Cas9 (dCas9) have been successfully derived by fusions with functional proteins that bind specific loci, or the activation or repression of gene activity at the target site (Chen et al., 2013; Gilbert et al., 2014; Konermann et al., 2015; Mandegar et al., 2016; Tanenbaum et al., 2014) (CRISPRa and CRISPRi, Figure 2). Some of these platforms have been successfully implemented for genome-wide screens and the manipulation of hPSCs. As demonstrated for TALE proteins and zinc finger DNA binding domains, the range of Cas9 could be extended in the future to also methylate or demethylate DNA or histones/chromatin at precise locations in the genome (Maeder et al., 2013; Meister et al., 2010). Moreover, dCas9 fused to fluorescent reporters has been developed to indicate nuclear organization by visualizing individual genomic loci (Chen et al., 2013; Gilbert et al., 2014; Tanenbaum et al., 2014). It is exciting that more applications are being developed; recently, Cas9 has been programmed to target RNA in vitro and in vivo (O’Connell et al., 2014; Nelles et al., 2016), raising the possibly that it could be used to better understand the transcriptome in addition to the genome.

Arguably the most far-reaching consequence of CRISPR/Cas9 gene targeting is the potential to edit the germline. Because gene editing by homologous recombination is inefficient, cells carrying the desired targeting event need to be selected in culture. Thus, germline modification in the past was restricted to mice as chimera-competent ESCs are not available in other species. Because CRISPR/Cas9 gene editing is so efficient, it requires no selection for the desired targeting events, rendering ESCs superfluous for the generation of mutant animals. CRISPR/Cas9 enabled gene editing in the zygote and was used to efficiently generate animals carrying defined mutations in multiple species including fish, Drosophila, mice, and primates (Bassett et al., 2013; Chang et al., 2013; Gratz et al., 2013; Hwang et al.,
Challenges and Next Steps

Despite the obvious advances that have been made as a result of iPSC and editing technologies, several challenges remain. A key limitation remains that human cells prefer to choose the imprecise NHEJ pathway to repair a DSB rather than use the more precise homologous DNA repair pathway using an exogenous repair template (Chapman et al., 2012). Due to this pathway choice, editing events often result in NHEJ-mediated insertions and deletions at the DSB rather than the intended homology-mediated modification. NHEJ-mediated gene disruption can be useful when the researcher or clinician intends to generate a loss-of-function event. However, in most clinical treatment settings the generation of a defined allele with high frequency will be essential to devise treatment options that require editing to result in gain of function at endogenous genes. Approaches to shift the balance away from NHEJ and toward homology-mediated repair included inhibiting NHEJ with small molecules or controlling the timing of CRISPR/Cas9 delivery with respect to the cell-cycle stage (Chu et al., 2015; Maruyama et al., 2015; Robert et al., 2015; Yu et al., 2015). These approaches are promising, yet we are currently far away from testing the efficacy of treatment strategies that rely on gene repair or gain-of-function approaches using high-frequency HR repair events of endogenous genes.

Facing this challenge, recent studies used creative ways to take advantage of NHEJ-mediated genome editing and the fact that the simultaneous expression of two nucleases can mediate the excision or inversion of the sequence internal to the two SSNs (Chiba et al., 2015; Chen et al., 2011; Young et al., 2016). In the specific case of Duchenne muscular dystrophy, Cas9 was employed to excise 725 kb of genomic sequences, which removed a premature STOP codon in the disease-causing DMD gene and thereby restored the reading frame and partial protein function (Young et al., 2016).

Similarly, Cas9-mediated genome editing in patient-specific iPSCs was used to genetically correct the disease-causing chromosomal inversions found in patients with Hemophilia A, demonstrating that NHEJ-based approaches can be used to model and correct large-scale genomic alterations underlying human disease (Park et al., 2015).

Elegant work that also takes advantage of the fact that genomic sequences between two SSN cuts can reinsert back into the locus in an inverted manner recently demonstrated that CTCF sites interact with each other in an orientation-dependent manner (Guo et al., 2015). Using this approach Guo et al. elucidate the impact of the directionality of CTCF sites in the mediation of large-scale genome interactions and transcriptional regulation.

Another challenge of genome editing in human cells is that human cells have relatively short conversion tracts (Elliott et al., 1998). This means that even when a DSB is repaired by homology-directed repair (HDR) and not the NHEJ machinery, modifications can only be made with reasonable frequency very close to one side of the DSB. This presents a major obstacle toward the introduction of complex genetic changes in hPSCs. The use of Cpf1, a class 2 CRISPR effector that uses the same basic principles as Cas9, but cleaves DNA further away from the PAM sequence and generates a single-stranded overhang, may help increase the rate of HDR over NHEJ events (Zetsche et al., 2015). Overcoming this challenge will significantly facilitate the engineering of human stem cells, as it will allow us to refine the human genome more efficiently. Eventually this could result in similar resources that have been used in yeast and mESCs, such as a comprehensive collection of conditional human knockout iPSC libraries, with a homozygous iPSC line for each human gene carrying an exon flanked by LoxP sites.

Rethinking the Ethical Debate

It will be important in the near future to navigate the ethical debate that arises from the confluence of genome editing with stem cell technology. This requires a policy framework that supports scientific progress that is independent of special interest groups that would bias a rational risk benefit assessment of this technology. The rampant progress that has been made over the last few years to improve genome editing technologies and to detect and reduce potential off-targets of SSNs has already lead to the first clinical trials for HIV, which are trail blazing through the necessary regulatory hurdles (Tebas et al., 2014). Somatic cell editing and editing in hPSCs in vivo and/or ex vivo coupled with transplantation will progress to become a standard clinical application. These efforts have to be clearly distinguished from editing human germ cells or totipotent cells of the early human embryo. Indeed, the efficiency of altering the genome of mammals by injecting CRISPR/Cas9 RNA or DNA into the fertilized egg (Wang et al., 2013) sparked a debate on whether this technology should be used to modify the human germline (Sheridan, 2015). While technical challenges currently limit the potential application of such modifications, two recent papers describe gene editing of the embryo’s genome following injection of gRNAs, CRISPR/Cas9 RNA, and targeting oligos into human zygotes (Kang et al., 2016; Liang et al., 2015). These studies raise a number of scientific issues such as off-target rate, mosaicism, and the likely alteration of the non-targeted wild-type allele when a mutant allele is targeted. More importantly, the technology raises serious ethical issues: do we want to irreversibly alter the human germline? Thus, the clinical application of this gene editing technology for medical purposes raises important ethical issues that will need to be widely discussed and agreed upon as it would affect future generations.

ACKNOWLEDGMENTS

We thank the members of the Hockemeyer laboratory for helpful discussion. D.H. is a New Scholar in Aging of the Ellison Medical Foundation and is supported by the Glenn Foundation as well as the The Shurl and Kay Curci Foundations. The work in the Hockemeyer laboratory is supported by NIH R01 CA196884-01, and in the Jaenisch laboratory, by NIH grants 1R01NS088538-01 and 2R01MH104610-15. R.J. is an advisor to Stemgent and Fate Therapeutics.

REFERENCES


adult stem cell properties derived from pluripotent stem cells. Stem Cell Reports 2, 838–852.


